Results 251 to 260 of about 127,480 (296)
Some of the next articles are maybe not open access.
Antibiotic treatment of acute bacterial skin and skin structure infections
Current Opinion in Infectious Diseases, 2022Purpose of review Acute bacterial skin and skin structure infections (ABSSSI) are a leading cause of morbidity, with a considerable variety of clinical presentation and a wide range of etiological pathogens. Of importance, the spread of multidrug-resistant (MDR) strains (i.e.
Russo, Alessandro +2 more
openaire +3 more sources
Managing acute bacterial skin and skin structure infections
The Nurse Practitioner, 2017Abstract: Acute bacterial skin and skin structure infections (ABSSSI) are some of the most commonly encountered infections worldwide. Hospitalizations as a result of ABSSSI are associated with high mortality. This article discusses the role of oritavancin and dalbavancin, two new lipoglycopeptides, in the context of the other I.
Allison M, Bell +5 more
openaire +2 more sources
Tedizolid for treatment of acute bacterial skin and skin structure infections
Expert Review of Anti-infective Therapy, 2015Tedizolid is a newly approved drug of the oxazolidinone class. It has high in vitro activity against Gram-positive bacteria, including multidrug-resistant strains. Peak plasma concentration of tedizolid is obtained within 3 h of oral dosing (PO), with high bioavailability.
Ye, Hui, Lü, Xiaoju
openaire +2 more sources
Oritavancin: A Review in Acute Bacterial Skin and Skin Structure Infections
Drugs, 2015Oritavancin (Orbactiv(®)) is a new generation lipoglycopeptide approved for use in adult patients with acute bacterial skin and skin structure infections (ABSSSI). It is administered as a single 1200 mg intravenous infusion over 3 h. In phase 3 trials in adult patients with ABSSSI, oritavancin was noninferior to vancomycin in terms of a composite ...
Yahiya Y, Syed, Lesley J, Scott
openaire +2 more sources
Expert Review of Anti-infective Therapy, 2023
Acute bacterial skin and skin structure infections (ABSSSIs) are a subtype of skin and soft tissue infections (SSTI), usually sustained by Gram-positive bacteria, whose incidence is high among children. ABSSSIs are responsible for a considerable number of hospitalizations.
Lorenzo Volpicelli +2 more
openaire +2 more sources
Acute bacterial skin and skin structure infections (ABSSSIs) are a subtype of skin and soft tissue infections (SSTI), usually sustained by Gram-positive bacteria, whose incidence is high among children. ABSSSIs are responsible for a considerable number of hospitalizations.
Lorenzo Volpicelli +2 more
openaire +2 more sources
Enriching the antibiotic armamentarium for acute bacterial skin and skin structure infections
The Lancet Infectious Diseases, 2019no abstract available ...
Bassetti M., Righi E.
openaire +4 more sources
Newest lipoglycopeptides for the management of acute bacterial skin and skin structure infections
The Nurse Practitioner, 2018Abstract: Acute bacterial skin and skin structure infections (ABSSSIs) are some of the most commonly encountered infections worldwide. Hospitalizations as a result of ABSSSIs are associated with high mortality. This article discusses the role of oritavancin and dalbavancin, the two newest lipoglycopeptides, in the context of the other ...
Allison M, Bell +5 more
openaire +3 more sources
Expert Opinion on Pharmacotherapy, 2012
Bacterial resistance is increasing on a global basis, making treatment options more limited. The development of new agents to meet this threat is a matter of urgency. Ceftaroline fosamil , a member of an advanced cephalosporin class of antimicrobials, is currently approved by the US Food and Drug Administration for use in for acute bacterial skin and ...
Anthony M, Casapao +3 more
openaire +2 more sources
Bacterial resistance is increasing on a global basis, making treatment options more limited. The development of new agents to meet this threat is a matter of urgency. Ceftaroline fosamil , a member of an advanced cephalosporin class of antimicrobials, is currently approved by the US Food and Drug Administration for use in for acute bacterial skin and ...
Anthony M, Casapao +3 more
openaire +2 more sources
Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections
Expert Review of Clinical Pharmacology, 2014Skin infections have traditionally been classified by the US FDA as uncomplicated and complicated. In August 2010, the FDA released a new guidance document for the development of drugs to treat acute bacterial skin and skin structure infections (ABSSSI) and this was updated in 2013.
Eric, Beresford +5 more
openaire +2 more sources